Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM® Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions.

Because NICU care is among the most expensive types of hospital care, reducing admissions has the potential to generate meaningful healthcare savings while improving newborn health outcomes. Four in ten U.S. births are to first-time mothers. Traditional risk assessment tools rely heavily on prior pregnancy history, which is not available in this population. The PreTRM Test enables early risk identification, creating an opportunity for early intervention and improved outcomes.

The findings, published in The Journal of Maternal-Fetal & Neonatal Medicine, highlight the clinical value of early risk stratification using the PreTRM® Test combined with accessible interventions in women in their first pregnancy, a large population in which risk is otherwise difficult to predict.